Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma

Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it can only extend limited survival. It is imperative to find a combination strategy to increase sorafenib efficacy. Artesunate is such a preferred candidate, because artesunate is clinically well-tolerated and m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Acta Pharmacol Sin
Hlavní autoři: Li, Zhong-jie, Dai, Hui-qi, Huang, Xiao-wei, Feng, Ji, Deng, Jing-huan, Wang, Zi-xuan, Yang, Xiao-mei, Liu, Yu-jia, Wu, Yong, Chen, Pan-hong, Shi, Huan, Wang, Ji-gang, Zhou, Jing, Lu, Guo-dong
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Singapore 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026986/
https://ncbi.nlm.nih.gov/pubmed/32699265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-020-0478-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky